EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

NCT00848510 | Completed Phase 1 Results

• 2 other identifiers: EMR 62242-0032008-001820-30
• Study Type: interventional
• Target: 41
• Locations: 1 country
• Sites: 1

Brief Summary

This study is intended to test an experimental drug called EMD 525797 (Abituzumab). This drug is not yet approved for sale and has only been tested in a small number of people to date (prior to this study starting another research study was carried out involving 37 healthy volunteers receiving the study drug). Until more is known about this study drug, it can only be used in research studies. This research study is planned to answer important questions about how the study drug is tolerated and how it may work in subjects with ovarian and colorectal cancer which has spread to the liver (i.e. metastatic cancer). The Sponsor (Merck KGaA) of this study is developing the study drug.

Conditions

Colorectal and Ovarian Cancer Patients With Liver Metastases

Outcome Measures

Primary Outcomes (5)

• Number of Subjects With Dose Limiting Toxicities (DLTs)

  Toxicity was graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. A DLT was defined as any Grade 3 or 4 haematological or non-haematological toxicity occurring during the first 4 weeks of treatment (that is, until the beginning of Week 5, with the exception of Grade 3 asymptomatic increase in liver function tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], and alkaline phosphatase \[ALP\]) returning to Baseline within 7 days.), at any dose level, for which a causal relationship to the investigative medicinal product could not be ruled out by the Investigator and/or the Sponsor.

  Up to Week 4

• Volume Transfer Coefficient of Contrast Agent Across the Capillary Walls

  Volume transfer coefficient was defined as the volume transfer coefficient of contrast agent across the capillary wall, reflecting endothelial permeability and blood flow. Volumetric transfer coefficient was measured by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). DCE-MRI is a noninvasive quantitative method of investigating microvascular structure and function by tracking the pharmacokinetics of injected low molecular weight contrast agents as they pass through tumor vasculature.

  Screening 1, screening 2, Week 1 Day 2, Week 1 Day 5, and Week 2 Day 1

• Blood Plasma Volume and Extravascular/Extracellular Volume

  Blood plasma volume and extracellular/extravascular volume was measured using DCE-MRI.

  Screening 1, screening 2, Week 1 Day 2, Week 1 Day 5, and Week 2 Day 1

• Initial Area Under the DCE-MRI Contrast Agent Concentration Time Curve After 60 Seconds (IAUC60)

  IAUC 60 was used to give a gross indication of the delivery and uptake of contrast agent within the tumor (indicating the degree of perfusion and endothelial permeability. IAUC60 was measured using DCE-MRI.

  Screening 1, screening 2, Week 1 Day 2, Week 1 Day 5, and Week 2 Day 1

• Whole Tumor Volume and Enhancing Tumor Volume

  Tumor volume (three-dimensional measurement) and the enhancing fraction of the tumor, which provides a gross measure of the proportion of the tumor that has a measurable level of perfusion, were assessed using DCE-MRI.

  Screening 1, screening 2, Week 1 Day 2, Week 1 Day 5, and Week 2 Day 1

Secondary Outcomes (5)

• Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death

  From the initiation of the trial treatment until 30 days after last administration of trial treatment.

• Number of Subjects With Best Overall Response, Tumor Response and Clinical Benefit

  Up to 4 years

• Number of Subjects With Worsened Post Baseline Shift in ECOG Performance Status Score

  Up to 4 weeks after last dose administration

• Number of Subjects With Positive Binding Abituzumab Antibodies

  Day 1 of Weeks 1, 3, 5, 6, 7, 8, and week 11 and end of study (EOS) visit (4 weeks after last dose administration)

• Progression-Free Survival (PFS) Time

  Time from first study drug intake to disease progression, death or last tumor assessment until end of trial visit (4 weeks after last dose administration)

Study Arms (1)

EMD 525797

EXPERIMENTAL

Biological: EMD 525797

Interventions

EMD 525797 BIOLOGICAL

Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease \[SD\], complete response \[CR\], or partial response \[PR\]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.

EMD 525797

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provision of signed written informed consent
• Male or female subjects, aged at least 18 years
• Subjects with liver metastases (3 to 10 centimeter \[cm\] diameter) from colorectal and ovarian cancers
• Failure of standard cancer therapy
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at study entry and an estimated life expectancy of at least 3 months
• Adequate haematological function, defined by absolute neutrophil count (ANC) greater than or equal to (\>=) 1.5 x 10\^9 per liter (/L), platelet count \>= 100 x 10\^9 / L, and haemoglobin concentration \>= 9 gram per deciliter (g/dL)
• As subjects with documented liver metastases are treated in this trial, liver function test values are accepted as followed: up to the upper limit of Grade 2 as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. This includes total bilirubin level less than or equal to (=\<) 3 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =\<5 x ULN
• Adequate renal function defined by serum creatinine =\<1.5 x ULN or a creatinine clearance of \>=50 milliliter per minute (mL/min) calculated by Cockcroft-Gault
• Effective contraception (example: double barrier method) for both male and female subjects if the risk of conception exists. These subjects must be willing to avoid pregnancy during the study (screening to end of study \[EOS\]) as well as for at least 3 months after the last dosing.

You may not qualify if:

• Any systemic cancer treatment within 30 days before treatment with EMD 525797
• Thrombolytics or oral or parenteral anticoagulants (except to maintain patency of preexisting, permanent indwelling intravenous catheters) within 10 days prior to study start and during treatment
• Radiotherapy, chemotherapy, surgery, or any investigational drug in the 30 days before the start of treatment in this study, and/or diagnostic biopsies within 2 weeks before the start of treatment in this study
• Previous treatment with anti-integrin therapy or anti angiogenic therapy within the last 6 months
• Confirmed or clinically suspected brain metastases
• Known hypersensitivity reactions to the study medication
• History of allergic reactions to other monoclonal antibody (mAb) therapy
• Uncontrolled hypertension (systolic blood pressure greater than (\>) 180 millimeter of mercury (mmHg), diastolic \>100 mmHg)
• Current history of chronic daily aspirin therapy (doses of =\< 150 mg is permitted), bleeding disorders, and/or history of thromboembolic events
• Severe peripheral vascular disease or ulceration
• Unstable angina pectoris, or myocardial infarction within 6 months before start of study treatment, clinical significant abnormal electrocardiogram (ECG) at screening;
• In women of childbearing potential, pregnancy (absence to be confirmed by beta human chorionic gonadotropin \[β HCG\] test, unless a subject has previously undergone hysterectomy or bilateral ovariectomy), or lactation period
• Known alcohol or drug abuse
• Participation in another clinical trial within the past 30 days before start of study treatment
• All other significant diseases which, in the opinion of the principal investigator (PI), might impair the subject's tolerance of study treatment

Sponsors & Collaborators

• Merck KGaA, Darmstadt, Germany: lead

Study Sites (1)

Christie Hospital

Manchester, United Kingdom

Location

MeSH Terms

Interventions

Abituzumab

Results Point of Contact

• Title: Merck KGaA Communication Center
• Organization: Merck Serono, a division of Merck KGaA

service@merckgroup.com

+49-6151-72-5200

Study Officials

• Medical Responsible

  Merck KGaA, Darmstadt, Germany

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 19, 2009
• First Posted: February 20, 2009
• Study Start: February 1, 2009
• Primary Completion: November 1, 2013
• Study Completion: November 1, 2013
• Last Updated: December 14, 2015
• Results First Posted: December 14, 2015

Record last verified: 2015-11

Locations

GB (1)